Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions

Solid Tumor, Adult

Interventions

DRUG

AK119

AK119 is an anti-CD73 monoclonal antibody.

DRUG

AK112

AK112 is a bispecific monoclonal antibody against VEGF and PD-1.

Trial Locations (1)

RECRUITING

Peking Union Medical College Hospital, Beijing